(NASDAQ: INAB) In8bio's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.95%.
In8bio's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast INAB's revenue for 2025 to be $1,217,820,992, with the lowest INAB revenue forecast at $1,217,820,992, and the highest INAB revenue forecast at $1,217,820,992. On average, 1 Wall Street analysts forecast INAB's revenue for 2026 to be $6,309,724,707, with the lowest INAB revenue forecast at $6,309,724,707, and the highest INAB revenue forecast at $6,309,724,707.
In 2027, INAB is forecast to generate $5,117,495,605 in revenue, with the lowest revenue forecast at $5,117,495,605 and the highest revenue forecast at $5,117,495,605.